Phase 1B CHM CORE-NK trial advances to newly diagnosed AML
Filed with ASX · · 2 pages · English
Chimeric Therapeutics Limited on 6ix
Story so far
Earlier from Chimeric Therapeutics
- Chimeric receives $4.17m R&D tax incentive
- AGM Presentation and CEO Appointment
- Reinstatement to Official Quotation
- $5 million Placement to progress CHM CDH17 trial
- AML patient achieves Complete Response in CHM CORE-NK trial
Later from Chimeric Therapeutics
- $4.0m Non-Dilutionary Funding
- Half Year Report and Appendix 4D 31 December 2024
- Suspension from Quotation
- Chimeric announces intention to undertake Entitlement Offer
- Reinstatement to Quotation
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics